STERIS plc (STE)
| Market Cap | 25.53B -2.5% |
| Revenue (ttm) | 6.17B +8.1% |
| Net Income | 826.90M +20.1% |
| EPS | 8.42 +20.8% |
| Shares Out | 97.11M |
| PE Ratio | 31.22 |
| Forward PE | 22.26 |
| Dividend | $2.76 (1.05%) |
| Ex-Dividend Date | Nov 17, 2026 |
| Volume | 340,460 |
| Open | 260.00 |
| Previous Close | 253.44 |
| Day's Range | 258.72 - 264.24 |
| 52-Week Range | 195.14 - 269.44 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | 281.14 (+6.93%) |
| Earnings Date | Nov 4, 2026 |
About STE
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. It operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. The company offers cleaning chemistries and sterility assurance products, automated endoscope reprocessing system and tracking products, endoscopy accessories, instruments, washers, and sterilizers and other pieces of capital equipment, as well as equipment used directly in the procedure rooms, including surgical tables, lights, e... [Read more]
Financial Performance
In fiscal year 2026, STERIS's revenue was $5.94 billion, an increase of 8.73% compared to the previous year's $5.46 billion. Earnings were $782.30 million, an increase of 27.29%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for STE stock is "Buy." The 12-month stock price target is $281.14, which is an increase of 6.93% from the latest price.
News
Steris upgraded to Buy from Hold at Jefferies
Jefferies upgraded Steris (STE) to Buy from Hold with a price target of $305, up from $232. The company offers a “steady” double-digit earnings grower below its average multiple with…
Steris price target raised to $290 from $270 at UBS
UBS analyst Patrick Wood raised the firm’s price target on Steris (STE) to $290 from $270 and keeps a Buy rating on the shares.
Steris files automatic mixed securities shelf
09:09 EST Steris (STE) files automatic mixed securities shelf
Steris price target raised to $284 from $269 at KeyBanc
KeyBanc analyst Brett Fishbin raised the firm’s price target on Steris (STE) to $284 from $269 on higher estimates and multiple, while keeping an Overweight rating on the shares. The…
STERIS Earnings Call Transcript: Q2 2027
Q2 revenue grew 9% and adjusted EPS rose 19%, with tariff refunds supporting margins. FY2027 EPS guidance increased; Life Sciences growth expectations rose while AST guidance was trimmed.
STERIS Earnings release: Q2 2027
STERIS released its Q2 2027 earnings on November 5, 2026, summarizing the period's financial results.
STERIS Quarterly report: Q2 2027
STERIS has published its Q2 2027 quarterly earnings report on November 5, 2026.
Steris reports Q2 adjusted EPS $2.94, consensus $2.68
Reports Q2 revenue $1.59B, consensus $1.56B. “We are pleased with our second quarter performance,” said Dan Carestio, President and CEO of STERIS (STE). “Life Sciences delivered particularly strong pe...
Steris sees FY27 adjusted EPS $11.35-$11.55, consensus $11.18
Previous view was $11.10-$11.30. Expectations for consolidated revenue growth are unchanged and include as reported revenue growth of 7-8% and constant currency organic revenue growth of 6-7%. Publish...
STERIS Announces Financial Results for Fiscal 2027 Second Quarter
DUBLIN, IRELAND, Nov. 04, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 second quarter ended September 30, 2026. Tot...
STERIS Announces Dividend of $0.69 per share
DUBLIN, IRELAND, Oct. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.69 per share. The divi...
STERIS to Host a Conference Call for Fiscal 2027 Second Quarter on November 5, 2026
DUBLIN, IRELAND, Oct. 20, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2027 second quarter resu...
Steris to acquire Xodus Medical, terms not disclosed
Xodus Medical announced that it has entered into an agreement to be acquired by Steris (STE), a global provider of products and services that support patient care with an emphasis…
Xodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE)
PITTSBURGH, Oct. 12, 2026 /PRNewswire/ -- Xodus Medical, a leading developer and manufacturer of innovative surgical safety solutions, today announced that it has entered into an agreement to be acqui...
Steris to Acquire Xodus Medical for $2.1 Billion
The Dublin, Ireland provider of products and services to hospitals and pharmaceutical manufacturers said it expects the deal to expand its portfolio.
STERIS Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Resilient healthcare demand, recurring revenue dominance, and strong endoscopy growth underpin stable mid to high single-digit top-line and double-digit bottom-line targets. Expansion in Europe, automation investments, and margin improvement initiatives support a positive multi-year outlook.
STERIS to Present at the Morgan Stanley Healthcare Conference
Dublin, Ireland, Sept. 01, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will participate in the Morgan Stanley Healthcare Conference in New York ...
Steris price target lowered to $270 from $275 at UBS
UBS lowered the firm’s price target on Steris (STE) to $270 from $275 and keeps a Buy rating on the shares.
STERIS Earnings Call Transcript: Q1 2027
Revenue grew 7% year-over-year with strong margin expansion and double-digit EPS growth. Healthcare and Life Sciences segments delivered robust organic growth, while a $600 million investment in a new chemistry center was announced. Fiscal 2027 guidance and dividend growth were reaffirmed.
STERIS Earnings release: Q1 2027
STERIS released its Q1 2027 earnings on August 6, 2026, summarizing the period's financial results.
STERIS Quarterly report: Q1 2027
STERIS has published its Q1 2027 quarterly earnings report on August 6, 2026.
Steris announces targeted restructuring plan
Steris (STE) is announcing a targeted restructuring plan in connection with its recent announcement to consolidate manufacturing and distribution for formulated chemistries to a new Center of Excellen...
Steris reports Q1 adjusted EPS $2.59, consensus $2.49
Reports Q1 revenue $1.5B, consensus $1.5B. “We are pleased with our performance in the first quarter,” said Dan Carestio, President and CEO of STERIS (STE). “Our first quarter results reflected…
Steris backs FY27 adjusted EPS view of $11.10-$11.30, consensus $11.16
Steris (STE) said: “The Company is reiterating its prior guidance for revenue and earnings for fiscal 2027. This includes as reported revenue growth of 7-8% and constant currency organic revenue…
STERIS Announces Financial Results for Fiscal 2027 First Quarter
DUBLIN, IRELAND, Aug. 05, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2027 first quarter ended June 30, 2026. Total rev...